The design and analysis of cholera vaccine trials: Recent lessons from bangladesh

International Journal of Epidemiology

Volumn 22, Issue 4, 1993, Pages 724-730

  Clemens, John ^a,b   Sack, David ^a,c   Rao, Malla ^a,b   Chakraborty, J ^a   Kay1, Bradford ^c,d   Ahmed, Faruque ^a,b   Khan, M R ^a   Vanloon1, Fpl ^e   Svennerholm, A M ^e   Holmgren, Jan ^d  

^a INTERNATIONAL CENTRE FOR DIARRHOEAL DISEASE RESEARCH   (Bangladesh)

^b EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^c JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^d UNIVERSITY OF GOTHENBURG   (Sweden)

^e CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLERA VACCINE;

AFRICA; ARTICLE; ASIA; BANGLADESH; BLOOD GROUP; CHOLERA; CLINICAL TRIAL; DATA ANALYSIS; HUMAN; INCIDENCE; METHODOLOGY; PRIORITY JOURNAL; SAMPLE; SOUTH AND CENTRAL AMERICA; VACCINATION;

AMERICAS; ASIA; BACTERIAL AND FUNGAL DISEASES; BANGLADESH; BIOLOGY; CLINICAL RESEARCH; CLINICAL TRIALS; COLOMBIA; DEMOGRAPHIC FACTORS; DEVELOPING COUNTRIES; DIARRHEA; DISEASES; EPIDEMIOLOGIC METHODS; IMMUNITY; IMMUNITY, NATURAL; INCIDENCE; INFECTIONS; LATIN AMERICA; LITERATURE REVIEW; MEASUREMENT; PERU; PHYSIOLOGY; POPULATION; POPULATION DYNAMICS; PROSPECTIVE STUDIES; RESEARCH METHODOLOGY; SEASONAL VARIATION; SOUTH AMERICA; SOUTHERN ASIA; STUDIES; VACCINES;

ABO BLOOD-GROUP SYSTEM; AGE FACTORS; BANGLADESH; CHILD, PRESCHOOL; CHOLERA; CHOLERA VACCINES; CLINICAL TRIALS; EPIDEMIOLOGIC METHODS; FOLLOW-UP STUDIES; FORECASTING; HUMAN; INCIDENCE; INFANT; POPULATION SURVEILLANCE; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RESEARCH DESIGN; RISK FACTORS; SELECTION BIAS; SEROTYPING; SUPPORT, NON-U.S. GOV'T; TREATMENT OUTCOME; VIBRIO CHOLERAE;

CHOLERA VACCINE; EPIDEMIOLOGICAL STUDY; VACCINE TRIAL;

BANGLADESH;

EID: 0027337566     PISSN: 03005771     EISSN: 14643685     Source Type: Journal    
DOI: 10.1093/ije/22.4.724     Document Type: Article

References (20)

1. Tauxe R V, Blake P A. Epidemic cholera in Latin America. JAMA 1992; 267: 1388-90.
2. Glass R, Claeson M, Blake P et al. Cholera in Africa: lessons on transmission and control for Latin America. Lancet 1991; 338: 791-95.
3. Clemens J, Stanton B. Longer term evaluations of vaccine efficacy. In: Woodrow G, Levine M M (eds). New Generation Vaccines. New York; Marcel Dekker, 1990, pp. 51-68.
4. Clemens J, Sack D A, Harris J et al. Field trial of oral cholera vaccines in Bangladesh: Results from three-year follow-up. Lancet 1990; 335: 270-73.
5. Glass R, Becker S, Huq M et al. Endemic cholera in rural Bangladesh. Am J Epidemiol 1982; 116: 959-70.
6. Clemens J, Sack D, Harris J et al. ABO blood groups and cholera: New observations on specificity of risk and modification of vaccine efficacy. J Infect Dis 1989; 159: 770-73.
7. Benenson A S. Review of experience with whole-cell and somatic antigen vaccines. In: Symposium on Cholera. Sapporo, Japan: Japanese Cholera Panel, US-Japan Cooperative Medical Science Program, 1976, pp. 228-41.
8. Glass R I, Khan M R, Greenough W B, Holmgren J. The use of family studies for prospective epidemiologic investigations of cholera. In: Proceedings of the 19th US-Japan Joint Cholera Conference. Bethesda, MD. 17-19 October 1983.
9. Craig M. Time-space clustering of Vibrio cholerae 01 in Matlab, Bangladesh, 1970-1982. Soc Sci Med 1988; 26: 5-13.
10. Donner A. An empirical study of cluster randomization. Int J Epidemiol 1982; 11: 283-86.
11. Clemens J D, Sack D A, van Loon FPL et al. Non-participation as a determinant of adverse health outcomes in a field trial of oral cholera vaccines. Am J Epidemiol 1992; 135: 865-74.
12. Clemens J, Stanton B, Harris J et al. Exclusion of clinically atypical or microbiologically mixed diarrhoeal episodes from outcome events in a field trial of oral cholera vaccines. Int J Epidemiol 1989; 18: 440-45.
13. Bart K J, Huq Z, Khan M, Mosley W H. Seroepidemiological studies during a simultaneous epidemic of infection with El Tor Ogawa and classical Inaba Vibrio cholerae. J Infect Dis 1970; 12l(Suppl.): S17-24.
14. Clemens J, Sack D, Rao M et al. Field trial of inactivated oral cholera vaccines in Bangladesh: evidence that vaccination both prevents and mitigates infection by Vibrio cholerae 01. J Ir\fect Dis 1992; 166: 1029-34.
15. Clemens J, Sack D, Harris J et al. Breast-feeding and the risk of severe cholera in rural Bangladeshi children. Am J Epidemiol 1990; 131:400-11.
16. Clemens J D, Harris J R, Kay BA et al. Oral cholera vaccines containing B subunit-killed whole cells and killed whole cells-only: II. Field evaluation of cross-protection against other members of the Vibrionaceae family. Vaccine 1989; 7: 111-20.
17. Clemens J, Sack D, Harris J et ai. Cross-protection by B subunit- whole cell cholera vaccine against diarrhoea associated with heat labile toxin-producing enterotoxigenic Escherichia coli: Results of a large-scale field trial. J Infect Dis 1988; 158; 372-77.
18. Clemens J, Harris J, Sack D et al. Field trial of oral cholera vaccines in Bangladesh: results of one year of follow-up. J Infect Dis 1988; 158: 60-69.
19. Levine M, Kaper J, Herrington D. Safety, immunogenicity, and efficacy in man of recombinant live oral cholera vaccines, CVD 103 and CVDa 103-HgT. Lancet 1988; 2: 467-70.
20. Jcrtbom M, Svennerholm A-M, Holmgren J. Safety and immunogenicity of an oral recombinant cholera B subunit-whole cell vaccine in Swedish volunteers. Vaccine 1992; 10: 130-32.